Routine intraoperative cholangiography during laparoscopic cholecystectomy: application of the 2016 WSES guidelines for predicting choledocholithiasis

Hui-Ying Lai1,2,3 · Kuei-Yen Tsai1,2,3 · Hsin-An Chen1,2,3

Received: 12 August 2020 / Accepted: 9 January 2021 / Published online: 1 February 2021
© The Author(s) 2021

Abstract

Background Routine use of intraoperative cholangiography (IOC) during laparoscopic cholecystectomy (LC) for detecting common bile duct stones remains controversial. The 2016 World Society of Emergency Surgery (WSES) guidelines on acute calculous cholecystitis proposed a risk stratification for choledocholithiasis. Our present study aimed to (1) examine the findings of common bile duct (CBD) stones in patients underwent LC with routine use of IOC, and (2) validate the 2016 WSES risk classes for predicting choledocholithiasis.

Methods All patients had LC with IOC routinely performed from November 2012 to December 2017 were reviewed retrospectively. Patients were classified into high-, intermediate-, and low-risk groups based on the 2016 WSES risk classes with modification.

Results A total of 990 patients with LC and routine IOC were enrolled. CBD stones were detected in 197 (19.9%) patients. The rate of CBD stone detected in low-, intermediate-, high-risk groups were 0%, 14.2%, and 89.6%, respectively. Predictors as following: evidence of CBD stones on abdominal ultrasound or computed tomography, CBD diameter > 6 mm, total bilirubin > 4 mg/dL, bilirubin level = 1.8–4 mg/dL, abnormal liver biochemical test result other than bilirubin, presence of clinical gallstone pancreatitis had statistical significance between patients with and without CBD stones. Major bile duct injury was found in 4 patients (0.4%). All 4 patients had uneventful recovery after repair surgery.

Conclusions Based on our study results, the 2016 WSES risk classes for choledocholithiasis could be an effective approach for predicting the risk of choledocholithiasis. Considering its advantages for detecting CBD stones and biliary injuries, the routine use of IOC is still suggested.

Keywords Intraoperative cholangiography · Laparoscopic cholecystectomy · Choledocholithiasis · Common bile duct stone · Bile duct injury

Since its first introduction in the 1930s, intraoperative cholangiography (IOC) has been used to detect choledocholithiasis, biliary anatomy, and iatrogenic bile duct injuries. A prevalence of 10%–18% for concurrent common bile duct (CBD) stones in patients undergoing laparoscopic cholecystectomy (LC) has been reported, which may result in future health problems, such as pain, jaundice, infection, and biliary pancreatitis, if not managed in a timely manner [1, 2]. According to data from a large Swedish registry, when CBD stones are found on IOC during cholecystectomy, there is a higher rate of unfavorable outcomes if no measures are taken intraoperatively or planned postoperatively [3]. In addition, as LC being one of the most common abdominal operations performed currently, iatrogenic bile duct injury has become more frequent. In open cholecystectomy, the average incidence of CBD injury is approximately 0.2%–0.4%; however, in laparoscopic procedures, the incidence can increase to 0.2%–1.7%, especially in complicated cases [4, 5]. More biliary injuries can be detected intraoperatively when IOC
is performed. Early detection and treatment of these injuries can prevent the further progression of partial injuries to complete CBD transections [6].

On the other hand, some stated that IOC increases the cost, operation time, and hospital stay, with no strong evidence indicating that it improves stone extraction and biliary injury rates [7]. When IOC was routinely performed, 10% of patients were found to have asymptomatic CBD stones, which may subsequently pass spontaneously or never cause any symptoms [8, 9].

So far, the need for routine IOC during LC remains controversial. As IOC is mostly performed when CBD stones are suspected, preoperative evaluation for the possibility of choledocholithiasis became a decisive factor. The 2016 World Society of Emergency Surgery (WSES) guidelines on acute calculous cholecystitis proposed a risk stratification for choledocholithiasis [10, 11]. Few studies have assessed the performance of existing guidelines for the prediction of choledocholithiasis [12, 13]. In these studies, CBD stones were diagnosed through endoscopic ultrasound (EUS), magnetic resonance cholangiopancreatography (MRCP), or endoscopic retrograde cholangiopancreatography (ERCP). Our present study examined the findings of CBD stones in laparoscopic cholecystectomy with routine intraoperative cholangiography, and aimed to (1) validate the 2016 WSES risk classes for predicting choledocholithiasis, (2) evaluate the performance of individual predictors, and (3) investigate the characteristics of patients susceptible to CBD stones. Cases with intraoperative bile duct injury were also recorded and further discussed.

Materials and methods

We retrospectively reviewed the data of 990 patients who underwent elective and emergency LC with IOC routinely performed from November 2012 to December 2017. All surgeries were performed by a single surgical team. Some patients with jaundice or suspected CBD stones clinically had ERCP prior to operation. Patients with or without preoperative ERCP were included. Data of preoperative evaluations: imaging studies, biochemistry data; perioperative findings such as operation time, IOC completion, positive IOC findings, conversion to open surgery rate, and bile duct injury, length of hospital stay, readmission rate, and mortality and morbidity were collected. This study was approved by the ethics committee of our hospital.

Operation method

A subumbilical incision was made through minilaparotomy to insert an 11-mm trocar, and insufflation of carbon dioxide was maintained at a pressure of 15 mm Hg. Surgery was performed using a 30° laparoscope. Another incision was made at the subxiphoid to insert another 11-mm trocar. In addition, two other incisions were performed at the midclavicular and right subcostal for inserting 5-mm trocars for placing two clamps to hold the gallbladder on its fundus and Hartmann pouch. L-hook electrocautery was applied for dissection.

After the cystic duct had been identified, a metallic clip was placed between the cystic duct and gallbladder neck. Subsequently, a small hole was created in the cystic duct with a laparoscopic scissor. An IOC catheter was inserted into the cystic duct and fixed with another clip. The biliary anatomy was visualized with a mobile C-arm. After no filling defect was found in the bile duct with adequate flow of contrast medium into the duodenum, the IOC catheter was removed, and operation was completed following the common procedure. Otherwise, laparoscopic common bile duct exploration (LCBDE) or postoperative ERCP was performed.

Risk classes

Patients were classified into high-, intermediate-, and low-risk groups based on the 2016 WSES risk classes with modification. Predictive factors included the following: preoperative abdominal ultrasound (AUS) or computed tomography (CT), bilirubin, liver function test, age, and gallstone pancreatitis clinically. Patients had high risk if they had evidence of CBD stones on AUS or CT; patients had intermediate risk if they had at least one of the other risk factors (CBD diameter > 6 mm, total bilirubin > 4 mg/dL, bilirubin level = 1.8–4 mg/dL, abnormal liver biochemical test result other than bilirubin, age > 55 years, and presence of clinical gallstone pancreatitis); and patients with none of these risk factors were classified into the low-risk group (Table 1).

Statistical analysis

Validity of the WSES classification for detecting choledocholithiasis and performance of individual risk factors were examined, and basic characteristics were compared between patients with or without CBD stones. Among patients receiving ERCP prior to LC, those with positive IOC findings during operations were further analyzed.

Baseline characteristics and predictive factors were compared using Student’s t test for continuous variables and Chi-square and Fisher’s exact test for categorical variables,
as appropriate. A p value of <0.05 was considered statistically significant. Individual predictor cut-off points were estimated using the receiver operator characteristic (ROC) curve. Statistical analysis was conducted using IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.

### Results

A total of 990 patients with LC and routine IOC were enrolled into this study. The study population comprised 498 male and 492 female patients (M:F ratio = 1:1). The mean age of our patients was 58.65 (± 16.12) years. Patients were admitted mainly for gallbladder stones (90%), and they had other surgery indications, including gallbladder tumor/polyps and CBD stones. Moreover, 131 patients had previous ERCP; 833 patients had elective surgery, and the remaining 157 had emergent surgery.

In this study, 128 patients had positive IOC findings; 120 had direct LCBDE, 4 had direct LCBDE with postoperative ERCP, 3 had postoperative ERCP (LCBDE failed due to the small caliber of CBD), and the stone was passed in another 1 patient after pushing contrast medium. Postoperative ERCP after direct LCBDE was arranged in 3 patients for large impacted stones that could not be removed, and in 1 patient, the contrast medium did not pass smoothly, although no filling defect was detected on IOC after LCBDE. In 33 patients, IOC was not performed successfully mostly because of the small caliber of the cystic duct or fragile tissue. In 11 patients, laparoscopic operations were converted to open surgery. The average operation time was 78.20 ± 35.34 min. The mean length of hospital stay was 3.06 ± 3.21 days.

Two patients died (1 had respiratory failure, and the other had postoperative bile leak with septic shock). Major bile duct injury was found in 4 patients. Immediate primary repairs were performed in 2 patients, and 1 patient underwent hepaticojejunostomy (HJ) after conversion into laparotomy. Another patient was readmitted on POD 8 and underwent primary repair through laparoscopy. The patient who underwent HJ had low risk, and other 3 patients had intermediate risk. All 4 patients had a smooth hospital course. Minor bile leak (defined as bile content in drainage found postoperatively) was found in 5 patients, and 2 patients had postoperative endoscopic retrograde biliary drainage (ERBD), whereas 3 patients recovered without specific intervention. Other postoperative complications were noted in 19 patients: respiratory-related complications in 5, intra-abdominal infection in 3, postoperative ileus in 2, wound infection in 2, iatrogenic small bowel perforation in 2, cardiovascular-related complication in 1, cholangitis in 1, urinary tract infection in 1, duodenum bleeding in 1, and stroke in 1 patient. Moreover, 36 patients were readmitted after operation, including 9 for CBD stones (Table 2).

CBD stones were detected in 197 (19.9%) patients. After applying the choledocholithiasis risk classification to our 990 patients, 318, 537, and 135 patients were included in the low-risk, intermediate-risk, and high-risk groups, respectively; the rate of CBD stone detection was 0%, 14.15%, and 89.63% in these groups, respectively. In the intermediate and high-risk groups, the risk classification had a sensitivity of 100% and specificity of 40.10% (accuracy: 52.02%) (Table 3).

| Table 1 Predictive factors and risk classes for choledocholithiasis |
|---------------------------------------------------------------|
| **Very strong** Evidence of CBD stones on AUS or CT**          |
| **Predictive factors for choledocholithiasis**                |
| Strong CBD diameter > 6 mm (with gallbladder in situ)         |
| Total bilirubin > 4 mg/dL                                     |
| Bilirubin level: 1.8–4 mg/dL                                  |
| Moderate Abnormal liver biochemical test other than bilirubin |
| Age > 55 years                                               |
| Clinical gallstone pancreatitis                               |
| **Risk classes for choledocholithiasis**                      |
| High Presence of any VERY STRONG predictors                  |
| Low No predictors present                                     |
| Intermediate All other patients                               |

Modified from [10, 11]

**In “very strong predictor,” this study also included CT as a diagnostic tool**

| Table 2 Perioperative findings and postoperative outcomes (N=990) |
|---------------------------------------------------------------|
| Positive IOC findings                                         |
| LCBDE                                                         |
| LCBDE → ERCP                                                  |
| ERCP                                                         |
| IOC failed                                                    |
| Conversion to open                                            |
| OP time (minutes)                                             |
| Main bile duct injury                                         |
| Primary repair                                                |
| Hepaticojejunostomy                                          |
| Postoperative complications                                   |
| Minor bile leak                                              |
| Length of stay (days)                                         |
| Readmission                                                  |
| For CBD stone                                                |
| Mortality                                                    |

n

| Positive IOC findings |
|-----------------------|
| LCBDE                 |
| LCBDE → ERCP          |
| ERCP                  |
| IOC failed            |
| Conversion to open    |
| OP time (minutes)     |
| Main bile duct injury |
| Primary repair        |
| Hepaticojejunostomy   |
| Postoperative         |
| Minor bile leak       |
| Length of stay (days) |
| Readmission           |
| For CBD stone         |
| Mortality             |

*One CBD stone was flushed out after pushing contrast medium*
Basic characteristics, imaging studies, and biochemical variables of patients with and without CBD stones are presented in Table 4. Among these parameters, statistically significant differences were found in age, total bilirubin, GOT, GPT, and CBD diameter (> 6 mm) between patients with and without CBD stones. Regarding the performance of individual predictors (Table 5), all these predictors, except “age > 55 years”, had statistical significance between patients with and without CBD stones. Further ROC curve analysis of age showed the optimal cut-off point to be 63.5 years old.

### Table 3 CBD stone detection performance

|                      | All (N=990) | Low risk (n=318) | Intermediate risk (n=537) | High risk (n=135) |
|----------------------|-------------|------------------|---------------------------|-------------------|
| ERCP first           | 131         | 0                | 47                        | 84                |
| Positive findings on ERCP | 103         | 0                | 40                        | 63                |
| Positive findings on IOC | 57          | 0                | 11                        | 46                |
| Both                 | 35          | 0                | 7                         | 28                |
| Direct LC            | 859         | 318              | 490                       | 51                |
| Positive findings on IOC | 72          | 0                | 32                        | 40                |
| Numbers of CBD stone detected | 197        | 0                | 76                        | 121               |
| CBD stone detection rate | 19.9%      | 0%               | 14.2%                     | 89.6%             |
| Sensitivity          | /           | /                | 100%                      |                   |
| Specificity          | /           | /                | 40.10%                    |                   |

*Statistically significant (p < 0.05)

### Table 4 Baseline characteristic comparisons of patients with/without CBD stones

|                | All (N=990) | CBD stone (+) (n=197) | CBD stone (-) (n=793) | p value |
|----------------|-------------|------------------------|------------------------|---------|
| Age            | 56.28 ± 15.40 | 59.94 ± 16.84         | 55.26 ± 14.84         | 0.012*  |
| Female         | 492         | 99                     | 393                    | 0.525   |
| BMI            | 25.71 ± 5.07 | 25.07 ± 4.41          | 25.89 ± 5.23          | 0.187   |
| WBC            | 8.69 ± 5.42 | 9.14 ± 4.07           | 8.56 ± 5.73           | 0.387   |
| Bil-T          | 1.29 ± 2.15 | 2.79 ± 3.94           | 0.87 ± 0.90           | <0.001* |
| GOT            | 68.12 ± 115.72 | 165.71 ± 185.72    | 41.05 ± 65.14         | <0.001* |
| GPT            | 69.02 ± 119.97 | 177.25 ± 203.94    | 40.31 ± 58.06         | <0.001* |
| CBD diameter > 6 mm | 208        | 163                   | 45                     | <0.001* |

*Statistically significant (p < 0.05)

### Table 5 Individual risk predictor performance

|                           | All (N=990) | CBD stone (+) (n=197) | CBD stone (-) (n=793) | p value |
|---------------------------|-------------|------------------------|------------------------|---------|
| Very strong predictor     |             |                        |                        |         |
| CBD stones on CT/AUS      | 135 (13.64%) | 115 (58.97%)          | 20 (2.52%)             | <0.001* |
| Strong predictor          |             |                        |                        |         |
| CBD > 6 mm                | 160 (16.16%) | 114 (58.16%)          | 46 (5.79%)             | <0.001* |
| Total bilirubin > 4 mg/dL | 37 (3.7%)   | 34 (17.35%)           | 3 (0.04%)              | <0.001* |
| Bilirubin 1.8–4 mg/dL     | 112 (11.31%) | 63 (31.63%)           | 49 (6.17%)             | <0.001* |
| Moderate predictor        |             |                        |                        |         |
| Abnormal liver biochemistry data | 349 (35.25%) | 157 (80.10%)     | 192 (24.18%)           | <0.001* |
| Age > 55 years            | 486 (49.09%) | 109 (55.61%)         | 377 (47.48%)           | 0.168   |
| Clinical gallstone pancreatitis | 33 (3.33%)   | 30 (15.31%)          | 3 (0.38%)              | <0.001* |

*Statistically significant (p < 0.05)
In this study, 131 patients received ERCP before LC, and 72 patients had successful stone retrieval. IOC was not conducted successfully in 2 of the 72 patients. For 70 patients who underwent subsequent LC with IOC, 10 patients had still had positive IOC findings. None of the patient characteristics showed significant differences between patients with and without residual CBD stone during IOC (Table 6).

## Discussion

In our study, 859 patients underwent direct LC, and approximately 13% of the study patients had positive IOC findings, similar to the results of other studies [14–16]. After applying the risk classification (Table 1), no CBD stones were detected among low-risk patients. This result suggests that there is no need for patients with none of the predictors to undergo IOC for detecting CBD stones. Although this risk classification showed low specificity and accuracy among intermediate and high-risk groups (sensitivity: 100%; specificity: 40.10%; accuracy: 52.02%), CBD stones were still found in almost 15% of the patients in the intermediate-risk group. Tabone et al. reported a case series with the selective use of IOC in 266 patients in 1308 cholecystectomies. CBD stones were found in 13.5% of patients who underwent IOC, and 72% of them had normal preoperative images [17]. Regarding further interventions to clear the bile duct are generally suggested, routine IOC should be considered in patients with intermediate risk.

A previous study had used similar risk classification for choledocholithiasis to verify the performance of individual predictors. It showed statistically significant differences in factors including CBD stones on abdominal US, ascending cholangitis, CBD diameter of > 6 mm on US, and gallstone pancreatitis. However, such predictors did not increase the accuracy or performance of risk classes [13]. Our study also found significant differences in all predictors, except for age. The ROC curve was then calculated, and a cut-off point of 63.5 years was found for age. However, as we re-sorted our study group, we found that most intermediate-risk patients had more than one risk predictor. In other words, our elderly patients often presented with both elevated liver function and serum bilirubin levels. Boland et al. and Cieslak et al. have noted higher liver function data in the elderly population [18, 19]. Thus, correlations between individual risk predictors need to be further clarified to determine the most precise evaluation tools.

In the subgroup of 72 patients who had previous ERCP for stone retrieval, CBD stones were still found on IOC in 10 patients (13.9%). However, no significant decisive predictors were detected in the subgroup. In a study of 345 patients who underwent endoscopic biliary sphincterotomy for CBD stone recurrence, patient-related risk factors, such as periamillary diverticulum, CBD diameter (> 15 vs. ≤ 15 mm), and quantity of stones, as well as procedure-related risk factors, including complete stone removal in the first session and lithotripsy, were associated with CBD stone recurrence [20].

In cases with persistent stone on patients who underwent ERCP before cholecystectomy, we tend to perform direct LCBDE if the CBD diameter is ≥ 8 mm. Although postoperative ERCP is also feasible, single-stage management shows advantages in terms of lower rate of technique failure, a fewer number of procedures, shorter hospital stay, and lower hospital charges [21, 22]. Also, if patients underwent LCBDE were found to have multiple CBD stones, have a clinical suspicion of residual stones or further stone formation, T-tube drainage would be used. With the T-tube, postop diagnostic and therapeutic choledochoscopy could also be performed. In our practice, a planned postoperative ERCP was mostly reserved for patients with a small diameter of CBD to prevent biliary stenosis after LCBDE.

In the present study, main biliary duct injury was found in 4 patients (0.4%), and immediate repairs were performed during operation in 3 patients. These injuries were small perforation of the main bile ducts, and no transection injury was found. In a population-based cohort study in Sweden, Törnqvist et al. reported a rate of 1.5% for iatrogenic bile duct injuries among 51,041 cholecystectomies. In that study, patients with early detection of a bile duct injury (during the primary operation) showed a higher survival rate than those with delayed detection. Moreover, the intention to perform IOC also reduced the risk of death [23]. Without IOC, intraoperative diagnosis of biliary injury was made in only 10%–20% of the patients. By contrast, 30–90% of the injury could be detected during operation when IOC was used, and most injuries could be repaired immediately, with satisfactory outcomes. Although IOC may not prevent all biliary injuries, routine application reduces the rate and severity of CBD injury [24–26].

Given the rarity of CBD injury and the actual risk reduction associated with IOC, it has been argued that its routine
application does not justify the increased time and cost. Flum et al. showed that routine IOC prevents 2.5 deaths for every 10,000 patients [26]. Ludwig et al. also reported that IOC can prevent CBD injury per 500–700 cholecystectomies, and the surgical management costs for a CBD injury are $8000–20,000 [27]. The cost of undetected bile duct injury with repair done in the late course is 16 times higher than the cost of the injury with immediate repair. Moreover, potential psychological, biological, and socially effects on patients with biliary injury should also be considered [28]. Because no accurate predictors or characteristics are available for identifying patients prone to bile duct injury, routine IOC may remain a cost-effective and safe approach [25].

Limitation

This study is limited by the fact that routine IOC was not compared with selective use. Correlations between each variable should also be considered. A randomized control study should be conducted.

Conclusion

Based on our study results, the 2016 WSES risk classes for choledocholithiasis could be an effective approach for predicting the risk of CBD stones. No CBD stone was detected in our 318 low-risk patients; yet CBD stones were found in 14.2% of the patients in the intermediate-risk group. Our results also indicate that despite undergoing preoperative ERCP, IOC should still be performed. Additionally, according to a literature review, IOC enables the early detection of bile duct injury, which facilitates more favorable survival and prognosis for patients. Considering its advantages for detecting CBD stones and biliary injuries, the routine use of IOC is still suggested.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00464-021-08305-4.

Compliance with ethical standards

Disclosures

Drs. Hui-Ying Lai, Kuei-Yen Tsai, and Hsin-An Chen have no conflicts of interest or financial ties to disclose.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Kharbutli B, Velanovich V (2008) Management of preoperatively suspected choledocholithiasis: a decision analysis. J Gastrointest Surg 12:1973–1980
2. Dasari BV, Tan CJ, Gurusamy KS, Martin DJ, Kirk G, McKie L, Diamond T, Taylor MA (2013) Surgical versus endoscopic treatment of bile duct stones. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858
3. Möller M, Gustafsson U, Rasmussen F, Persson G, Thorell A (2014) Natural course vs interventions to clear common bile duct stones: data from the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde Cholangiopancreatography (GallRiks). JAMA Surg 149:1008–1013
4. Fletcher DR, Hobbs MS, Tan P, Valinsky LJ, Hockey RL, Pikora TJ, Knuiman MW, Sheiner HJ, Edis A (1999) Complications of cholecystectomy: risks of the laparoscopic approach and protective effects of operative cholangiography: a population-based study. Ann Surg 229:449–457
5. Ludwig K, Bernhardt J, Steffen H, Lorenz D (2002) Contribution of intraoperative cholangiography to incidence and outcome of common bile duct injuries during laparoscopic cholecystectomy. Surg Endosc 16:1098–1104
6. Woods M, Traverso L, Kozarek R, Donohue J, Fletcher D, Hunter J, Oddsdottir M, Rossi R, Tsao J, Windsor J (1995) Biliary tract complications of laparoscopic cholecystectomy are detected more frequently with routine intraoperative cholangiography. Surg Endosc 9:1076–1080
7. Ding G-Q, Cai W, Qin M-F (2015) Is intraoperative cholangiography necessary during laparoscopic cholecystectomy for cholelithiasis? World J Gastroenterol 21:2147
8. Verbesey JE, Birkett DH (2008) Common bile duct exploration for choledocholithiasis. Surg Clin North Am 88:1315–1328
9. Horwood J, Figsvari T, Clark L, Mangan J, Morgan R (2010) Prospective evaluation of a selective approach to cholangiography for suspected common bile duct stones. Ann R Coll Surg Engl 92:206–210
10. Ansaloni L, Pisano M, Coccolini F, Peitzmann A, Fingerhut A, Catena F, Agresta F, Allegri A, Bailey I, Balog JZ (2016) 2016 WSES guidelines on acute calculus cholecystitis. World J Emerg Surg 11:25
11. Maple JT, Ben-Menachem T, Anderson MA, Appalaneni V, Banerjee S, Cash BD, Fisher L, Harrison ME, Fanelli RD, Fukami N (2010) The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointest Endosc 71:1–9
12. Adams MA, Hosmer AE, Wamsteker EJ, Anderson MA, Elta GH, Kubilium NM, Kwon RS, Piraka CR, Scheiman JM, Waljee AK (2015) Predicting the likelihood of a persistent bile duct stone in patients with suspected choledocholithiasis: accuracy of existing guidelines and the impact of laboratory trends. Gastrointest Endosc 82:88–93
13. Narváez-Rivera RM, González-González JA, Monreal-Robles R, García-Compeán D, Paz-Delgadillo J, Garza-Galindo AA, Maldonado-Garza HJ (2016) Accuracy of ASGE criteria for the prediction of choledocholithiasis. Rev Esp Enferm Dig 108:309–314
14. Clayton E, Connor S, Alexakis N, Leandros E (2006) Meta-analysis of endoscopy and surgery versus surgery alone for common bile duct stones with the gallbladder in situ. Br J Surg 93:1185–1191

 Springer
15. Ebner S, Rechner J, Beller S, Erhart K, Riegler F, Szinicz G (2004) Laparoscopic management of common bile duct stones. Surg Endosc 18:762–765

16. Vezakis A, Davides D, Ammori B, Martin I, Larvin M, McMahon MJ (2000) Intraoperative cholangiography during laparoscopic cholecystectomy. Surg Endosc 14:1118–1122

17. Tabone LE, Sarker S, Fisichella PM, Conlon M, Fernando E, Yi S, Luchette FAJS (2011) To ‘gram or not’? Indications for intraoperative cholangiogram 150:810–819

18. Boland BS, Dong MH, Bettencourt R, Barrett-Connor E (2014) Loomba RJJc, hepatology e. Association of serum bilirubin with aging and mortality 4:1–7

19. Cieslak KP, Baur O, Verheij J, Bennink RJ, van Gulik TM (2016) Liver function declines with increased age. HPB (Oxford) 18:691–696

20. Li S, Su B, Chen P, Hao J (2018) Risk factors for recurrence of common bile duct stones after endoscopic biliary sphincterotomy. J Int Med Res 46:2595–2605

21. Gilsdorf D, Henrichsen J, Liljestrand K, Staheli A, Olsen G, Narayanan P, Ott M, Morris DS, Price R (2018) Laparoscopic common bile duct exploration for choledocholithiasis: analysis of practice patterns of intermountain healthcare. J Am Coll Surg 226:1160–1165

22. Jiang C, Zhao X, Cheng S (2019) T-Tube Use After Laparoscopic Common Bile Duct Exploration. JSLS. https://doi.org/10.4293/JSLS.2018.00077

23. Törnqvist B, Strömberg C, Persson G, Nilsson M (2012) Effect of intended intraoperative cholangiography and early detection of bile duct injury on survival after cholecystectomy: population based cohort study. BMJ 345:e6457

24. Alvarez F, De Santibañes M, Palavecino M, Sánchez Clariá R, Mazza O, Arbues G, de Santibañes E, Pekolj J (2014) Impact of routine intraoperative cholangiography during laparoscopic cholecystectomy on bile duct injury. Br J Surg 101:677–684

25. Flum DR, Dellinger EP, Cheadle A, Chan L, Koepsell T (2003) Intraoperative cholangiography and risk of common bile duct injury during cholecystectomy. JAMA 289:1639–1644

26. Flum DR, Flowers C, Veenstra DL (2003) A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. J Am Coll Surg 196:385–393

27. Ludwig K, Bernhardt J, Lorenz D (2002) Value and consequences of routine intraoperative cholangiography during cholecystectomy. Surg Laparosc Endosc Percutan Tech 12:154–159

28. Pekolj J, Alvarez F, Palavecino M, de Santibañes EJ (2013) Impact of routine intraoperative cholangiography during laparoscopic cholecystectomy on bile duct injury. BJS. https://doi.org/10.1002/bjs.9486

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.